Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165295 · ClinicalTrials.gov registry record · Phase 2
Sildenafil Citrate in Waldenstrom's Macroglobulinemia
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00165295 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants.
The verdict
NCT00165295, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects (good or bad) that sildenafil (Viagra) has on patients with slow growing Waldenstrom's macroglobulinemia (WM). Sildenafil blocks the function of several proteins necessary to the survival of certain types of cancer and laboratory tests have shown that it can destroy WM cells.
Interventions
- DRUG Sildenafil citrate (Viagra)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00165295
The ClinicalTrials.gov registry entry for NCT00165295 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sildenafil citrate (Viagra) is the first listed.
NCT00165295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00165295 about?
NCT00165295 is a clinical study titled "Sildenafil Citrate in Waldenstrom's Macroglobulinemia". The purpose of this study is to determine the effects (good or bad) that sildenafil (Viagra) has on patients with slow growing Waldenstrom's macroglobulinemia (WM). Sildenafil blocks the function of several proteins necessary to the survival of certain types of cancer and laboratory tests have shown...
What is the current status of trial NCT00165295?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-09. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00165295?
The interventions under investigation include: Sildenafil citrate (Viagra) (DRUG).
Who is sponsoring clinical trial NCT00165295?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.